These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23669150)

  • 41. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
    Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
    J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
    Niehaus A; Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW; Adamovich E
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):136-43. PubMed ID: 16198062
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Iodine-125 brachytherapy for localized prostate cancer and urinary morbidity: a prospective comparison of two seed implant methods-preplanning and intraoperative planning.
    Matzkin H; Kaver I; Stenger A; Agai R; Esna N; Chen J
    Urology; 2003 Sep; 62(3):497-502. PubMed ID: 12946754
    [TBL] [Abstract][Full Text] [Related]  

  • 44. (125)Iodine prostate brachytherapy: outcome from the first 100 consecutive patients and selection strategies incorporating urodynamics.
    Henderson A; Cahill D; Laing RW; Langley SE
    BJU Int; 2002 Oct; 90(6):567-72. PubMed ID: 12230619
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acute urinary retention after I-125 prostate brachytherapy in relation to dose in different regions of the prostate.
    Roeloffzen EM; Monninkhof EM; Battermann JJ; van Roermund JG; Moerland MA; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):76-84. PubMed ID: 20605364
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
    Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W
    Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long term outcome and side effects in patients receiving low-dose I125 brachytherapy: a retrospective analysis.
    Logghe P; Verlinde R; Bouttens F; Van den Broecke C; Deman N; Verboven K; Maes D; Merckx L
    Int Braz J Urol; 2016; 42(5):906-917. PubMed ID: 27532118
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rectal morbidity following I-125 prostate brachytherapy in relation to dosimetry.
    Ohashi T; Yorozu A; Toya K; Saito S; Momma T; Nagata H; Kosugi M
    Jpn J Clin Oncol; 2007 Feb; 37(2):121-6. PubMed ID: 17255159
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Permanent implant prostate cancer brachytherapy: 2013 state-of-the art].
    Cosset JM; Hannoun-Lévi JM; Peiffert D; Delannes M; Pommier P; Pierrat N; Nickers P; Thomas L; Chauveinc L
    Cancer Radiother; 2013 Apr; 17(2):111-7. PubMed ID: 23478488
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison between high and low source activity seeds for I-125 permanent seed prostate brachytherapy.
    Masucci GL; Donath D; Tétreault-Laflamme A; Carrier JF; Hervieux Y; Larouche RX; Bahary JP; Taussky D
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):781-6. PubMed ID: 20171808
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Segmental dosimetry, toxicity and long-term outcome in patients with prostate cancer treated with permanent seed implants.
    Meyer A; Wassermann J; Warszawski-Baumann A; Baumann R; Machtens S; Karstens JH; Christiansen H; Merseburger A; Kuczyk MA; von Klot C
    BJU Int; 2013 May; 111(6):897-904. PubMed ID: 23305079
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rectal morbidity after permanent prostate brachytherapy with dose escalation to biologic target volumes identified by SPECT/CT fusion.
    Ellis RJ; Zhou H; Kaminsky DA; Fu P; Kim EY; Sodee DB; Colussi V; Spirnak JP; Whalen CC; Resnick MI
    Brachytherapy; 2007; 6(2):149-56. PubMed ID: 17434109
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Permanent implant brachytherapy for early, organ-confined prostate cancer].
    Agoston P; Major T; Fröhlich G; Baricza K; Szabó Z; Lövey J; Varjas G; Kásler M; Fodor J; Polgár C
    Magy Onkol; 2011 Sep; 55(3):170-7. PubMed ID: 21918742
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predictive Factors for Prolonged Urination Disorder After Permanent
    Mori H; Fukumori T; Daizumoto K; Tsuda M; Kusuhara Y; Fukawa T; Yamamoto Y; Yamaguchi K; Takahashi M; Kubo A; Kawanaka T; Furutani S; Ikushima H; Kanayama HO
    In Vivo; 2017; 31(4):755-761. PubMed ID: 28652453
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Peak flow rate is the best predictor of acute urinary retention following prostate brachytherapy: our experience and literature review.
    Ikeda T; Shinohara K
    Int J Urol; 2009 Jun; 16(6):558-60. PubMed ID: 19456987
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Temporal resolution of urinary morbidity following prostate brachytherapy.
    Merrick GS; Butler WM; Lief JH; Dorsey AT
    Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):121-8. PubMed ID: 10758313
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of pre-implant lower urinary tract symptoms on postoperative urinary morbidity after permanent prostate brachytherapy.
    Teishima J; Iwamoto H; Miyamoto K; Shoji K; Masumoto H; Inoue S; Kobayashi K; Kajiwara M; Matsubara A
    Int J Urol; 2012 Dec; 19(12):1083-9. PubMed ID: 22852805
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Incidence and clinical course of hemorrhagic radiation proctitis after iodine-125 prostate brachytherapy.
    Mishra MV; Shirazi R; Barrett WL
    Clin Genitourin Cancer; 2007 Sep; 5(6):397-400. PubMed ID: 17956713
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictive factors of rectal toxicity after permanent iodine-125 seed implantation: Prospective cohort study in 2339 patients.
    Katayama N; Yorozu A; Maruo S; Kojima S; Ohashi T; Tanaka N; Kikuchi T; Higashide S; Saito S; Dokiya T; Fukushima M; Yamanaka H
    Brachytherapy; 2016; 15(6):736-745. PubMed ID: 27720311
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds.
    Bottomley D; Ash D; Al-Qaisieh B; Carey B; Joseph J; St Clair S; Gould K
    Radiother Oncol; 2007 Jan; 82(1):46-9. PubMed ID: 17161481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.